Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Drug

CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+

Fineline Cube May 12, 2026
Company

Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC

Fineline Cube Jan 23, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food...

Company Deals

Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies

Fineline Cube Jan 23, 2025

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...

Company

Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook

Fineline Cube Jan 23, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting...

Company Drug

YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia

Fineline Cube Jan 23, 2025

Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...

Company Drug

Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials

Fineline Cube Jan 23, 2025

China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid,...

Company Deals

iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies

Fineline Cube Jan 23, 2025

Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7...

Company Drug Medical Device

Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook

Fineline Cube Jan 23, 2025

US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8%...

Company Deals

Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials

Fineline Cube Jan 23, 2025

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...

Company Drug

Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease

Fineline Cube Jan 23, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from...

Company Deals

Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote

Fineline Cube Jan 23, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial

Fineline Cube Jan 23, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...

Company Medical Device

Roche’s cobas liat STI Assay Panels Gain FDA Approval and CLIA Waiver

Fineline Cube Jan 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced receiving approval from the US...

Company Drug

United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease

Fineline Cube Jan 23, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jan 23, 2025

France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval in the European Union...

Company Deals

Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing

Fineline Cube Jan 23, 2025

US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...

Company Deals

Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody

Fineline Cube Jan 22, 2025

China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...

Company Deals

Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2025

China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...

Company Deals

Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development

Fineline Cube Jan 22, 2025

China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...

Company Drug

FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial

Fineline Cube Jan 22, 2025

France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...

Company Drug

Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder

Fineline Cube Jan 22, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...

Posts pagination

1 … 219 220 221 … 663

Recent updates

  • AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
  • CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+
  • GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Company Drug

CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.